Abstract Objective-to examine the effect of cycle phase or a low dose oral conraceptive on exercise performance in young women. Methods-As controls, 15 men were tested twice by a maximal treadmill test (Vo2 max) and by an endurance run 14 d apart to determine performance variability from causes other than hormonal fluctuations. Ten women ages 18-30 were then tested for VO2 max and endurance in the same way in both the follicular and the luteal phase (random order, ovulation assessed by sonography). They were then randomly assigned to placebo (n = 3) or oral contraceptive (1 mg norethindrone and 35 pg ethinyl oestradiol) (n = 7) for 21 days. Tests were repeated during the first and third weeks of treatment. Vo2 max and endurance tests were compared in the men and control cycle of the women by using independent t tests on percent change. The data for both cycles in the women were analysed by repeated measures ANOVA. Conclusions-Neither cycle phase nor a low dose oral contraceptive containing 1 mg norethindrone adversely affects performance during a maximal treadmill test or endurance run. (BrJ Sports Med 1996;30:36-40) 
twice by a maximal treadmill test (Vo2 max) and by an endurance run 14 d apart to determine performance variability from causes other than hormonal fluctuations. Ten women ages 18-30 were then tested for VO2 max and endurance in the same way in both the follicular and the luteal phase (random order, ovulation assessed by sonography). They were then randomly assigned to placebo (n = 3) or oral contraceptive (1 mg norethindrone and 35 pg ethinyl oestradiol) (n = 7) for 21 days. Tests were repeated during the first and third weeks of treatment. Vo2 max and endurance tests were compared in the men and control cycle of the women by using independent t tests on percent change. The data for both cycles in the women were analysed by repeated measures ANOVA.
Results-There was no difference in per cent change in total test time, Vo2 Athletic amenorrhea is a condition which affects many young women who participate in strenuous athletic sports. Although the exact mechanisms which lead to this condition are not clearly understood, it is clear that blood levels of oestradiol and progesterone are reduced in these women. Oestrogen treatment has been advocated to prevent osteoporosis associated with exercise induced hypogonadotropic hypogonadism (athletic amenorrhoea). Unopposed oestrogens, however, are associated with an increase in adverse endometrial effects such as carcinoma and dysfunctional uterine bleeding; these may be avoided by the addition of a progestational agent. Since combination oral contraceptives contain a progestin as well as an oestrogen, such a formulation appears to be a convenient method of replacement therapy.
The observation that the physiological increase in ventilation that occurs during pregnancy is mediated by progesterone has led to the investigation of the effect of various progestational agents upon respiratory function. 1 used to determine differences in endurance test variables between the follicular and luteal phase of the control cycle and pill phase 1 and phase 2 of the experimental cycle. Results are expressed as mean (SD) throughout the text. A probability level (P) of 0 05 was selected as the criterion for statistical significance.
Results
During the control cycle, ultrasound in the 10 female subjects showed development and rupture at the time of expected ovulation. During the second cycle, the three subjects who received placebo were found to have follicle development and rupture. One of the seven subjects who received oral contraceptives developed a 10 mm follicle which then ceased to grow. The remaining six subjects receiving contraceptives had no follicle development. Figure 1 represents data from the maximum stress test for the men and the first cycle of the women. There were no differences in total test time, V02 max, or breathing frequency between tests 1 and 2 in the women or the men: women: total test time 11 6 (SD 2 3) v 11L9 (2 2) min; V02 max 40-2 (8 9) v 39-3 (10-9) ml kg-'lmin'; breathing frequency 27-4 (4.2) v 27-3 (4 6) breaths min'; men: total test time 11 9 (2 2) v 12-3 (2-6) min; Vo2max 493 (94) v 51L5 (1 1.5) ml kgI-min-'; breathing frequency 27-4 (51) v 27-0 (5-0) breaths-min', respectively.
As expected, Vo2 max was higher in the men then in the women. The first two tests were done without regard to phase of the menstrual cycle and showed that repeating the test did not produce a learning effect. There were no differences in percent change for total test time, V02 max, or breathing frequency between men and women. Figure 2 represents the results of the endurance run for the men and the control cycle of the women. There was no difference between Figure 3 represents the results from the maximum stress test for the control and pill cycle in the women. It had previously been shown that the order of tests was not a factor in determining results, therefore, the control cycle was divided into the follicular and luteal phase. The pill cycle was also divided into phases 1 and 2. There was no difference between the follicular and luteal phase of the menstrual cycle for total test time, V02 max, or breathing frequency: total test time 11 -8 phases 1 and 2 of the pill cycle, no differences were observed for total test time, Vo2 max, or breathing frequency. Figure 4 shows the results from the endurance run for the control and pill cycle in the women. The endurance run was used to approximate athletic performance more cldsely. There was no significant difference between the follicular and luteal phase of the menstrual cycle for total test time, Vo2 max, or breathing frequency: total test time 20-8 (13.1) v 18-0 (12-5) min; Vo2max 36-2 (9 3) v 35-2 (8 3) ml kgl -min-'; breathing frequency 32-0 (6 0) v 33-2 (5 1) breaths-min-', respectively. There was also no difference in each of these variables between phase 1 and 2 of the pill cycle: total test time 31-3 (32-0) v 30-6 (27-5) min; Vo2 max 34.5 (9-3) v 35-4 (7-8) ml-kg-'min'-; breathing frequency 34 0 (5-9) v 34-8 (5-3) breaths-min-', respectively. There was no difference in total test time, Vo2 max, or breathing frequency when the data were compared between the control and pill cycle. long term adverse effects upon their health. It has been recommended that oestrogen replacement be offered to such individuals in order to prevent further bone loss and perhaps partially restore that which has already been lost. The inclusion of a progestational agent is common to prevent adverse effects of unopposed oestrogen treatment on the uterus. The effect of this medication on athletic performance has received limited attention.
The observation that natural progesterone was much more effective than the synthetic progestins anhyrohydroxy progesterone, norethinyl testosterone, and 1-2 dehydroprogesterone in stimulating ventilation in patients with pulmonary disease led to the suggestion that the side chain substitution in some way diminished the effect of synthetic progestins upon respiration.2 However, Skatrud et al later showed that the synthetic progestin medroxyprogesterone acetate (MPA) also stimulated ventilation.' The administration of MPA did not cause a deterioration in exercise performance, although some subjects did complain of increased exertional dyspnoea.3 "0 Oral contraceptives containing 1 mg norethindrone or 1 mg ethynodiol were also found to stimulate respiration but again did not appear to compromise exercise performance.6 In contrast, Notelovitz et al described a 7% deterioration in exercise performance in women using an oral contraceptive containing 0 4 mg norethindrone7; and Daggett and coworkers described an 11% deterioration in performance with an oral contraceptive containing 0-25 mg levonorgestral.5
Initial observations on our data suggest a trend toward deterioration in maximum oxygen uptake and endurance during the luteal phase, and an apparent improvement in endurance while using the oral contraceptive. Chronic oral contraceptive use has been shown to enhance growth hormone responses, lower blood glucose levels, and diminish carbohydrate oxidation during prolonged treadmill exercise." This could theoretically enhance prolonged exercise by facilitating an increased reliance on fats while having a carbohydrate sparing effect. Statistical analysis of our data does not, however, support the view that cycle phase or a low dose oral contraceptive has an effect of upon Vo2 max or endurance. The large variation in the level of conditioning and the resulting large standard deviation in the measured variables may be the reason for the lack of significance. Analysis of data on individual subjects, however, also failed to show an effect of cycle phase or the use of oral contraceptives upon Vo2 max or endurance.
The suggestion that the use of oral contraceptives will diminish athletic performance has led many trainers, coaches, and athletes to avoid their use, thus depriving the female athlete of the many benefits that the pill has to offer. Our findings suggest that a low dose oral contraceptive does not adversely affect performance during a maximal treadmill test. Perhaps more importantly, the lack of effect of the pill during an endurance run could have far reaching effects upon recommendations for health care in women. 
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